

# OMEGA THERAPEUTICS, INC. Reported by VARSALONE JEFFREY T

## FORM 3

(Initial Statement of Beneficial Ownership)

## Filed 02/04/25 for the Period Ending 01/24/25

Address 140 FIRST STREET, SUITE 501

CAMBRIDGE, MA, 02141

Telephone (617) 949-4360

CIK 0001850838

Symbol OMGA

SIC Code 2836 - Biological Products, (No Diagnostic Substances)

Industry Biotechnology & Medical Research

Sector Healthcare

Fiscal Year 12/31



## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Statement (N			ement (MM/DD/YYYY)		3. Issuer Name and Ticker or Trading Symbol Omega Therapeutics, Inc. [OMGA]			
(Last) (First) (Middle)	4. Relat	ionship of R	Reportin	g Person(s) to Issuer (	erson(s) to Issuer (Check all applicable)			
C/O OMEGA THERAPEUTICS INC., 140 FIRST STREET, SUI 501	· · · · · · · · · · · · · · · · · · ·			10% Owner Other (specify be	low)			
(Street)  CAMBRIDGE, MA 02141  (City) (State) (Zip)		nendment, D M/DD/YYYY)	Oate Ori	X Form filed by O	6. Individual or Joint/Group Filing(Check Applicable Line)  _X_Form filed by One Reporting Person Form filed by More than One Reporting Person			
	Tab	le I - Non-D	)erivati	ve Securities Benefic	ally Owned			
1.Title of Security (Instr. 4)			Beneficially Owned (Instr. 4) (C		-	4. Nature of Indirect Beneficial Ownership (Instr. 5)		
Table II - Deriva	ive Securities	Beneficially	y Owne	ed (e.g., puts, calls, wa	arrants, options	, convertible secu	urities)	
1. Title of Derivate Security (Instr. 4)	and Expirat	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		e and Amount of ties Underlying ative Security 4)	4. Conversion or Exercise Price of Derivative	Form of	6. Nature of Indirect Beneficial Ownership (Instr. 5)	
	Date Exercisable	-		Amount or Number of Shares	Security	Indirect (I) (Instr. 5)		

#### **Explanation of Responses:**

#### Remarks:

Exhibit 24 - Power of Attorney

No securities are beneficially owned.

#### **Reporting Owners**

Danastina Orana Nama / A 11	Relationships			
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Varsalone Jeffrey T C/O OMEGA THERAPEUTICS, INC. 140 FIRST STREET, SUITE 501 CAMBRIDGE, MA 02141	X			

#### **Signatures**

/s/ Barbara Chan as Attorney-in-Fact for Jeffrey T. Varsalone

2/4/2025

\*\*Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

ersons who respond to the collection of information contained in this form are not required to respond unless the form displays a cur umber.	rently valid OMB control

#### POWER OF ATTORNEY

With respect to holdings of and transactions in securities issued by Omega Therapeutics, Inc. (the "Company"), the undersigned hereby constitutes and appoints the individuals named on <u>Schedule A</u> attached hereto and as may be amended from time to time, or any of them signing singly, with full power of substitution and resubstitution, to act as the undersigned's true and lawful attorney-in-fact to:

- 1. execute for and on behalf of the undersigned, Schedules 13D and 13G in accordance with Section 13 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the rules thereunder, and Forms 3, 4, and S in accordance with Section 16 of the Exchange Act and the rules thereunder, and Notices of Proposed Sale of Securities Pursuant to Rule 144 ("Form 144"), in accordance with the requirements of Rule 144 under the Securities Act of 1933, as amended (the "Securities Act"); and
- 2. do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Schedule 13D, Schedule 13G, Form 3, Form 4, Form S, and Form 144, complete and execute any amendment or amendments thereto, and to timely file such Schedule 13D, Schedule 13G, Form 3, Form 4, Form 5, and Form 144, as applicable, and any amendment thereto, with the United States Securities and Exchange Commission and any stock exchange or similar authority.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution and resubstitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorneys-in-fact substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted.

The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 13 and Section 16 of the Exchange Act, or Rule 144 under the Securities Act.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file any Schedule 13D, Schedule 13G, Form 3, Form 4, Form 5, and Form 144 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 28th day of January 2025.

Signature:	/s/ Jeffrey T. Varsalone			
	Jeffrey T. Varsalone			

### Schedule A

Individuals Appointed as Attorney-in-Fact with Full Power of Substitution and Resubstitution:

Kaan Certel Barbara Chan